 Home > Active Ingredient News > Blood System > Lancet Oncol: Use CAR T cell Axicabtagene ciloleucel to treat relapsed/refractory indolent non-Hodgkin's lymphoma

Lancet Oncol: Use CAR T cell Axicabtagene ciloleucel to treat relapsed/refractory indolent non-Hodgkin's lymphoma

 Last Update: 2021-12-26
 Source: Internet
 Author: User

Tags

28 3 lead

multiple pterygium syndrome

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Most patients with advanced indolent non-Hodgkin's lymphoma experience multiple relapses
.

This study aims to evaluate the efficacy of autologous anti-CD19 chimeric antigen receptor (CAR) T cell axicabtagene ciloleucel in the treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma

ZUMA-5 is a single-arm, multi-center phase 2 trial carried out in 17 medical centers in France and the United States, recruiting histologically confirmed relapses or refractory that have been treated twice before 18 years of age or older Patients with indolent non-Hodgkin's lymphoma (follicular lymphoma or marginal zone lymphoma) are treated with leukocyte depletion and pretreatment chemotherapy, and then a single dose of axicabtagene ciloleucel (2x106 CAR T cells/kg) is infused
.

The primary endpoint is the overall response rate

Remission rate

From June 20, 2017 to July 16, 2020, a total of 153 patients were recruited to undergo leukocyte depletion, and all patients successfully received axicabtagene ciloleucel
.

As of September 14, 2020, 148 patients had received an infusion of axicabtagene ciloleucel (124 [84%] follicular lymphoma and 24 [16%] marginal zone lymphoma)

96 (92%) achieved remission, of which 77 (74%) achieved complete remission, 96 (92%) achieved remission, of which 77 (74%) achieved complete remission

Progression-free survival

The most common grade 3/4 adverse reactions are cytopenia (70%) and infection (18%)
.

Ten patients had a grade ≥3 cytokine release syndrome, and 28 patients had a grade 3/4 neurological event

In summary, Axicabtagene ciloleucel has shown a high durable response rate and controllable safety in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma

Axicabtagene ciloleucel has shown high durable response rate and controllable safety in patients with relapsed or refractory indolent non-Hodgkin lymphoma .

Original source:

Caron A Jacobson, et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.